Literature DB >> 10385050

Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance.

A Di Troia1, M Carpo, N Meucci, C Pellegrino, S Allaria, F Gemignani, A Marbini, R Mantegazza, R Sciolla, E Manfredini, G Scarlato, E Nobile-Orazio.   

Abstract

Neuropathy has been frequently reported in patients with IgG monoclonal gammopathy of undetermined significance (MGUS) but it is still unclear whether this association has clinical or pathogenetic relevance. In order to clarify the possible role of IgG MGUS in the neuropathy we correlated the clinical and electrophysiological features of the neuropathy with the duration and anti-neural activity of the M-protein in 17 patients with neuropathy and IgG MGUS. Ten patients (59%) had a chronic demyelinating neuropathy clinically indistinguishable from chronic inflammatory demyelinating polyneuropathy (CIDP) while 7 (41%) had a predominantly sensory axonal or mixed neuropathy. In 80% of patients in the CIDP-like and 28% in the sensory group the IgG M-protein became manifest several months to years after onset of the neuropathy. Antibodies to one or more neural antigens (including tubulin, a 35KD P0-like nerve myelin glycoprotein, GD1a, GM1 and chondrotin sulfate C) were found in 40% of patients with CIDP-like and 43% with sensory neuropathy but also in 37% patients with IgG MGUS without neuropathy. Neuropathy associated with IgG MGUS is probably less heterogeneous than previously considered suggesting that this association may not be merely casual. The evidence for primary pathogenetic role of IgG M-proteins in the neuropathy remains however elusive.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10385050     DOI: 10.1016/s0022-510x(99)00049-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

Review 1.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

Review 2.  Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.

Authors:  Hafsa M Chaudhry; Michelle L Mauermann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2017-05       Impact factor: 7.616

Review 3.  Advances in the Treatment of Paraproteinemic Neuropathy.

Authors:  Eduardo Nobile-Orazio; Mariangela Bianco; Andrea Nozza
Journal:  Curr Treat Options Neurol       Date:  2017-10-16       Impact factor: 3.598

Review 4.  Treatment of dys-immune neuropathies.

Authors:  Eduardo Nobile-Orazio
Journal:  J Neurol       Date:  2005-04       Impact factor: 4.849

Review 5.  An update on monoclonal gammopathy and neuropathy.

Authors:  Sindhu Ramchandren; Richard A Lewis
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

Review 6.  Treatment for IgG and IgA paraproteinaemic neuropathy.

Authors:  Abraham C J Stork; Michael P T Lunn; Eduardo Nobile-Orazio; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2015-03-24

7.  Multiple Myeloma Associated Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Importance of Continued Surveillance.

Authors:  Adebayo A Fasanya; Michael F Loncharich; Viral Gandhi; Sandeep Rana; Marvin Balaan
Journal:  Cureus       Date:  2016-11-28

8.  Distinctive patterns of peripheral neuropathy across the spectrum of plasma cell disorders.

Authors:  Ja Min Byun; Young Nam Kwon; Youngil Koh; Sung-Soo Yoon; Jung-Joon Sung; Inho Kim
Journal:  Sci Rep       Date:  2019-11-14       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.